Triple-Drug cocktail targets tough melanoma

NCT ID NCT02721459

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new three-drug combination for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The drugs are XL888 (an HSP90 inhibitor), vemurafenib, and cobimetinib. The main goal is to find the safest dose of XL888 when given with the other two drugs, and to see how well patients tolerate the combination. Only 26 participants are enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XL888 (HSP90 inhibitor) combined with vemurafenib and cobimetinib
What this could lead to: If this works, it could point toward a more effective drug combination for advanced melanoma that has spread or cannot be removed by surgery.
What could go wrong: This is a very early (Phase 1) trial with only 26 people, focused on finding a safe dose. It is too small and early to know if the combination actually helps patients live longer or better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600 MUTATED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA SKIN CANCER

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.